Safety and Durability of Sirolimus for Treatment of LAM

Launched by UNIVERSITY OF CINCINNATI · May 1, 2015

Keywords

ClinConnect Summary

The MIDAS study is researching the safety and effectiveness of a medication called sirolimus for treating a rare lung disease known as lymphangioleiomyomatosis (LAM). The goal of this trial is to learn more about how well sirolimus works for patients who are currently using it, those who have previously tried it but experienced problems, or those who may need to use it in the future. This study is open to both men and women aged 18 and older, including adult females with tuberous sclerosis complex (TSC), whether or not they have lung cysts.

If you decide to participate, you will be asked to attend at least one clinic visit each year and provide consent to be part of the study. During the trial, you may undergo tests to check how well your lungs are functioning. It’s important to know that this study is currently recruiting participants, so if you meet the eligibility criteria, your involvement could contribute valuable information to help improve treatment options for LAM patients.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Female or male, age 18 or over
• • Diagnosis of LAM based on ATS/JRS criteria
• • Signed and dated informed consent
• • On chronic therapy, newly treated or may be considered for therapy with mTOR inhibitors or previously intolerant of or having failed mTOR inhibitor therapy
• Exclusion Criteria:
• • Inability to attend at least one RLD Clinic visit per year
• • Inability to give informed consent
• • Inability or unwillingness to perform pulmonary function testing